Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–38 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Skin Fibroblasts Clear all
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Dermagraft(R), Profore
Device
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
34
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
PEG-interferon alfa-2b
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
32
States / cities
Birmingham, Alabama • Lakeland, Florida • Bloomington, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced May 21, 2026, 6:54 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Cholangiocarcinoma
Interventions
LY4337713
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
20
States / cities
Newport Beach, California • Stanford, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 6:54 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Morphea, Scleroderma, Localized, Scleroderma
Interventions
FCX-013, veledimex
Genetic · Drug
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Acne Scarring of the Face
Interventions
Autologous Human Fibroblasts (azficel-T), Placebo
Biological
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Beverly Hills, California • San Diego, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced May 21, 2026, 6:54 PM EDT
Enrolling by invitation Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Hypochondroplasia
Interventions
infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
3 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Solid Tumors
Interventions
BGJ398, BYL719
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Tampa, Florida • Ann Arbor, Michigan • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced May 21, 2026, 6:54 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Achondroplasia
Interventions
Not listed
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
30 Months to 17 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Wilmington, Delaware + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced May 21, 2026, 6:54 PM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
FCX-007 (dabocemagene autoficel; see below for FCX-007 description)
Biological
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
2 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2037
U.S. locations
5
States / cities
Stanford, California • Aurora, Colorado • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced May 21, 2026, 6:54 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
Interventions
Futibatinib, Futibatinib plus Fulvestrant
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Phoenix, Arizona • San Francisco, California • Fort Myers, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced May 21, 2026, 6:54 PM EDT
Terminated Phase 3 Interventional
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
ABH001, Control wound treatment
Biological · Other
Lead sponsor
Shire Regenerative Medicine, Inc.
Industry
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Phoenix, Arizona • Redwood City, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced May 21, 2026, 6:54 PM EDT
Enrolling by invitation Phase 2 Interventional
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Infigratinib
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
3 Years to 18 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced May 21, 2026, 6:54 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Amputation, Skin Wound, Stem Cell
Interventions
Autologous Skin Fibroblasts, Placebo
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced May 21, 2026, 6:54 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
0 Years to 32 Months
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Oakland, California • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 6:54 PM EDT